-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A large number of splenomegaly with hypersplenism seriously affects the quality of life of thalassemia patients.
Ruxotinib (JAK1 and -2 inhibitor) has been approved for the treatment of primary myelofibrosis (MF), polycythemia vera (PV) post-MF and primary thrombocythemia MF , the main purpose is to reduce Small spleen size
Russo erlotinib (JAKl and -2 inhibitors) has been approved for the treatment of primary myelofibrosis (MF), after polycythemia vera (PV) MF and essential thrombocythemia the MF , , the main purpose is Reduce the size of the spleen
This case introduces a short case series of four thalassemia patients (age 26-36 years; 3 transfusion dependent and 1 non-transfusion dependent), in which the dose of ruxolitinib is 50% of the dose used in the TRUTH study.
This case introduces a short case series of four thalassemia patients (age 26-36 years; 3 transfusion dependent and 1 non-transfusion dependent), in which the dose of ruxolitinib is 50% of the dose used in the TRUTH study.
Table: Baseline and follow-up (F/u) values of complete blood count and spleen length (measured by ultrasound) for all four patients, and the total duration of ruxotinib treatment for each patient
Figure: A, B, C, and D respectively show the change trend of hemoglobin and platelet counts, absolute neutrophil counts and spleen size of patients (case 1, case 2, case 3, and case 4) from baseline to the last follow-up
FIG: A, B, C, D show the patient (Case 1, Case 2, Case 3 and Case 4) from baseline to the last follow-up hemoglobin and platelet counts, absolute neutrophil count and spleen size trends FIG.In all four patients, spleen size and physical symptoms related to splenomegaly were significantly reduced
In all four patients, spleen size and physical symptoms related to splenomegaly were significantly reduced
All in all, a therapeutic trial of Ruxotinib can be considered to avoid splenectomy for a large number of patients with splenomegaly and hypersplenism
Original source:
Original source:Taneja, K.
Taneja, K.
, Verma, C.
and Mahajan, A.
(2021), Can ruxolitinib avert splenectomy in patients with thalassaemia: a short term case series.
Br J Haematol.
https://doi.
org/10.
1111/bjh.
17871 https://doi.
org/10.
1111/bjh.
17871
Leave a message here
